Fabienne Thomas

21PUBLICATIONS
81CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Digital processor architecturesPharmacogenomicsRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 18, 2026
Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?

|Jan 27, 2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff

|Dec 11, 2025
Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy.

Matthieu Gracia, Sabrina Marsili, Julien Vintejoux

|Dec 03, 2024
Large-Scale DPD Testing Should Be More Than an Option.

Marie-Christine Etienne-Grimaldi, Bernard Royer, Manon Launay

|Aug 14, 2024
Reply to: "Is uracil enough for effective pre-emptive DPD testing?"

Fabienne Thomas, Manon Launay, Laure Raymond

|Jun 19, 2024
Can we identify patients carrying targeted deleterious <i>DPYD</i> variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis.

Manon Launay, Laure Raymond, Jérôme Guitton

Pageof 4

Frequent Collaborators

4 joint publications

Etienne Chatelut

3 joint publications

Félicien Le Louedec

3 joint publications

Mélanie White-Koning

3 joint publications

Manon Launay